Get Live Data

Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally
Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globallyView Video
Firering Strategic Minerals : from explorer to producer
Firering Strategic Minerals: From explorer to producerView Video

Latest Share Chat

  2. Share Prices
  3. Abzena Share Price
  4. Abzena Share Regulatory News
  5. Edison initiates coverage of Abzena Plc

Pin to quick picksAbzena Regulatory News (ABZA)

Abzena Information
  • There is currently no data for ABZA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison initiates coverage of Abzena Plc

2 Mar 2015 12:51

RNS Number : 2567G
Abzena PLC
02 March 2015
 

 

London, UK, 2 March 2015

Edison initiates coverage on Abzena

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Abzena

Click on, or paste the following link into your web browser, to view the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/2567G_-2015-3-2.pdf

Highlights of the analysis on Abzena by Edison's pharma & biotech analysts Christian Glennie and Dr Mick Cooper include:

Abzena offers a range of key services and technologies for the development of safer and more effective biological products. Antitope (immunogenicity testing, protein engineering, cell line development) and PolyTherics (bioconjugation, polymer/synthetic chemistry) are the operating business units.

Our fair value for Abzena is £95m (97.5p/share), based on a three-phase DCF of the services business (£35.5m) and risk-adjusted royalties from existing and future licensed antibody/ADC products (£43m). Cash of £18.7m (at 30 September 2014), after a £20m IPO on AIM, provides financial stability and flexibility to seek new assets.

To download this report, please click here.

 

All reports published by Edison are available to download free of charge from its website www.edisongroup.com.

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact:

Christian Glennie Edison Investment Research +44 (0)20 3077 5727

Dr Mick Cooper Edison Investment Research +44 (0)20 3077 5734 healthcare@edisongroup.com

Contact details: Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn

www.linkedin.com/company/edison-investment-research

Twitter

www.twitter.com/Edison_Inv_Res

YouTube

www.youtube.com/edisonitv

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAADAELESEFF
1234
Date   Source Headline
11th Apr 20173:06 pmRNSDirector/PDMR Shareholding
7th Apr 20171:36 pmRNSGrant of options
5th Apr 20173:45 pmRNSResult of bookbuild
5th Apr 20177:00 amRNSProposed Placing of £25m
6th Mar 20177:00 amRNS'Abzena inside' product enters Phase II trial
3rd Mar 20177:00 amRNSPartner Halozyme to present poster at AACR
1st Mar 20177:00 amRNSMRC grant awarded to collaboration group
21st Feb 20177:01 amRNSAntibody manufacturing development agreement
21st Feb 20177:00 amRNSTrading and business update
8th Feb 20178:43 amEQSEdison issues outlook on Abzena
6th Feb 201710:55 amRNSTotal Voting Rights
31st Jan 201712:53 pmRNSHardman Research: ThioBridge deal update
24th Jan 20177:00 amRNSIssue of Equity
20th Jan 20177:00 amRNSThioBridge license agreement
9th Jan 20179:37 amRNSBlocklisting update
22nd Dec 20167:00 amRNSLicence agreement
13th Dec 20167:15 amRNSHardman Research: Opening new doors
30th Nov 20167:00 amRNSHalf year results
23rd Nov 20168:09 amRNS'Abzena inside' product study data to be presented
15th Nov 201612:42 pmRNSNotice of half year results
2nd Nov 20167:00 amRNSLicensed product candidate update
24th Oct 20167:00 amRNSSenior Executive Appointments
21st Oct 20167:00 amRNSLicensed product candidate update
22nd Sep 20169:30 amRNSLicensed product candidate update
19th Sep 20162:28 pmRNSChange of Nominated Adviser and Broker
14th Sep 20163:58 pmRNSEdison issues research update on Abzena (ABZA)
13th Sep 20163:41 pmRNSResult of AGM
13th Sep 20167:00 amRNSDirectorate Change
13th Sep 20167:00 amRNSAGM Business Update
16th Aug 201612:20 pmRNSDirector/PDMR Shareholding and Exercise of Options
9th Aug 20162:30 pmRNSNotice of AGM
28th Jul 201611:45 amRNSEdison issues research update on Abzena (ABZA)
25th Jul 20167:00 amRNSManufacturing agreement
14th Jul 201610:37 amRNSJoint venture with Baylor Research Institute
6th Jul 20163:58 pmRNSBlock Listing Update
27th Jun 20164:46 pmRNSDirector Dealings
24th Jun 20169:45 amRNSExercise of warrants
22nd Jun 201610:12 amRNSEdison issues research review on Abzena (ABZA)
15th Jun 20164:09 pmRNSAnnual Report and Accounts
14th Jun 20167:00 amRNSFull year results
26th May 20167:00 amRNSNotice of Results
5th Apr 20169:20 amRNSExercise of Employee Share Options
1st Apr 20169:48 amRNSExercise of Share Options and Director Dealings
16th Mar 20169:45 amRNSExercise of Employee Share Options
9th Mar 201612:47 pmRNSExercise of Employee Share Options
9th Mar 20167:00 amRNSBusiness update
8th Feb 20163:14 pmRNSExercise of employee share options
4th Feb 20162:33 pmRNSHolding(s) in Company
25th Jan 20167:00 amRNSSignificant licence deal for ThioBridgeT
18th Jan 20167:00 amRNSAntitope collaboration awarded European grant
1234

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.